Impact of spironolactone on endothelial function in patients with single ventricle heart

Congenital Heart Disease

Volumn 4, Issue 1, 2009, Pages 12-16

  Mahle, William T ^a   Wang, Alicia ^b   Quyyumi, Arshed A ^a   McConnell, Michael E ^a   Book, Wendy M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial function; Fontan; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; C REACTIVE PROTEIN; CARVEDILOL; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOOP DIURETIC AGENT; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG TOLERABILITY; ENDOTHELIUM; FOLLOW UP; HEART FAILURE; HEART SINGLE VENTRICLE; HUMAN; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY;

ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; CARDIAC SURGICAL PROCEDURES; CHI-SQUARE DISTRIBUTION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SPIRONOLACTONE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59849100126     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2008.00240.x     Document Type: Article

References (19)

1. Cetta F, Feldt RH, O'Leary PW, et al. Improved early morbidity and mortality after Fontan operation: The Mayo Clinic experience, 1987 to 1992. J Am Coll Cardiol. 1996;28:480-486.
2. Khairy P, Fernandes SM, Mayer JE, Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85-92.
3. Binotto MA, Maeda NY, Lopes AA. Altered endothelial function following the Fontan procedure. Cardiol Young. 2008;18:70-74.
4. Inai K, Saita Y, Takeda S, Nakazawa M, Kimura H. Skeletal muscle hemodynamics and endothelial function in patients after Fontan operation. Am J Cardiol. 2004;93:792-797.
5. Jin SM, Noh CI, Bae EJ, Choi JY, Yun YS. Impaired vascular function in patients with Fontan circulation. Int J Cardiol. 2007;120:221-226.
6. Mahle WT, Todd K, Fyfe DA. Endothelial function following the Fontan operation. Am J Cardiol. 2003;91:1286-1288.
7. McCrindle BW, Williams RV, Mitchell PD, et al. Relationship of patient and medical characteristics to health status in children and adolescents after the Fontan procedure. Circulation. 2006;113:1123-1129.
8. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-431.
9. Stephens MB. Selective aldosterone blockade reduces mortality after MI. J Fam Pract. 2003;52:598-599.
10. Funder J. Mineralocorticoids and cardiac fibrosis: The decade in review. Clin Exp Pharmacol Physiol. 2001;28:1002-1006.
11. Pitt B, Stier CT, Jr., Rajagopalan, S. Mineralocorticoid receptor blockade: New insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:164-168.
12. Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: Relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123-126.
13. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
14. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail. 2006;12:240-245.
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
16. Abiose AK, Mansoor GA, Barry M, Soucier R, Nair CK, Hager D. Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol. 2004;93:1564-1566.
17. Villacorta H, Masetto AC, Mesquita ET. C-reactive protein: An inflammatory marker with prognostic value in patients with decompensated heart failure. Arq Bras Cardiol. 2007;88:585-589.
18. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47:1687-1694.
19. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.